Arbutus Biopharma (ABUS) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Arbutus Biopharma Corporation, a clinical-stage company focused on developing treatments for chronic hepatitis B, is set to engage with investors at two major conferences in New York. They will present at the H.C. Wainwright Global Investment Conference and have a fireside chat at the Baird Global Healthcare Conference, with live webcasts available for both events.
For further insights into ABUS stock, check out TipRanks’ Stock Analysis page.